---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-003903"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2024-01-16T23:59:59+00:00"
generated_at: "2026-06-06T23:03:42.153278+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Protagonist details rusfertide Ph3 enrollment, JNJ-2113 milestones, cash runway through Q1 2026

## Summary
- Rusfertide VERIFY Ph3 enrollment expected to complete 1Q24; NDA filing planned for Q4 2024.
- JNJ-2113 ICONIC Ph3 program ongoing; ANTHEM UC Ph2b expected completion ~May 2025.
- Oral IL-17 peptide antagonist development candidate on track for 2024.
- Cash runway forecast through Q1 2026; $215M potential milestones from Janssen not included.
- $172.5M in upfront and development milestones achieved, including $60M in Q4 2023.

## SEC filing metadata
- accession: 0001104659-24-003903
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2024-01-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465924003903/0001104659-24-003903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465924003903/tm243318d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-003903
- JSON: https://secwatch.observer/filing/0001104659-24-003903.json
- Plain text: https://secwatch.observer/filing/0001104659-24-003903.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.